NEW YORK (GenomeWeb) – Epic Sciences has raised $30 million in a Series C round of private financing that it will use to support development of its circulating tumor cell analysis platform.

The San Diego-based firm is developing a circulating rare cell analysis platform with a particular focus on developing products and services to detect CTCs in cancer. It plans to market molecular diagnostic tests that rapidly quantify proteomic and genomic changes that occur over time during the treatment of a patient's cancer from a minimally invasive liquid biopsy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.